M&A / Deals Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb PharmaTimesPartnership to develop nextgeneration Tcell engagers for solid tumoursM&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) PharmaTimes Partnership to develop nextgeneration Tcell engagers for solid tumours M&A / DealsRead full story Post navigation Previous: Innovent’s CDMO gets green light to make biologics at large Chinese plantNext: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026